Summary of Palisade Bio FY Conference Call Company Overview - **Company**: Palisade Bio (NasdaqCM:PALI) - **Industry**: Biotechnology, specifically focusing on oral therapeutics in the Inflammatory & Immune (I&I) space - **Lead Drug**: PALI-2108, a PDE4 inhibitor developed for treating inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis [2][3] Core Points and Arguments Drug Development and Mechanism - PALI-2108 is a prodrug formulation that releases its active ingredient in the lower gastrointestinal (GI) tract, avoiding adverse events associated with traditional PDE4 inhibitors, such as secretory diarrhea and CNS events like headache and nausea [3][4] - The drug has shown efficacy in treating IBD diseases, with a focus on reducing adverse events by localizing the drug's action [3][4] Clinical Trials and Milestones - Completed preclinical development and initiated clinical trials, treating 84 healthy volunteers and 5 ulcerative colitis patients in a Phase 1b cohort [4][5] - A small cohort study in fibrostenotic Crohn's disease is expected to read out by the end of March 2026 [5] - Plans to file an Investigational New Drug (IND) application for ulcerative colitis in May 2026, with patient treatment starting in early Q3 2026 and data readout by the end of 2027 [5][13] Market Potential - Crohn's disease and ulcerative colitis are identified as multi-billion dollar markets, with fibrostenotic Crohn's disease being a significant unmet need as there are currently no approved therapies [14] - The company aims to differentiate itself by being the first dual-acting anti-inflammatory and anti-fibrotic drug in development for fibrostenotic Crohn's disease [11][14] Competitive Landscape - Competitors include Agomab, which recently IPO'd at over $750 million, and other PDE4 inhibitors like AstraZeneca's roflumilast and Amgen's Otezla [12][14] - The company is developing a precision medicine test to identify potential responders to PALI-2108, enhancing its competitive edge [12][19] Financial Overview - Completed a transformational financing in October 2025, providing sufficient funds to support definitive studies in both ulcerative colitis and fibrostenotic Crohn's disease, with a runway extending into 2029 [28][29] - The company maintains a clean capital structure with 206 million shares fully diluted [28][29] Key Insights and Considerations - The drug's design aims to minimize common PDE4-related adverse events, which could enhance its market acceptance [43][44] - The company emphasizes its capital efficiency and execution capabilities, which may be underappreciated in the market [47][48] - There is ongoing evaluation regarding whether to pursue a broader indication for Crohn's disease or focus specifically on fibrosing Crohn's, pending data from the Phase 1b cohort [31][33] Conclusion Palisade Bio is positioned in a promising niche within the biotechnology sector, focusing on innovative oral therapeutics for IBD. The company's strategic development of PALI-2108, along with its financial backing and market potential, presents a compelling case for investors looking for opportunities in the healthcare space.